JP2008529537A - プリオン特異的なペプチド試薬 - Google Patents
プリオン特異的なペプチド試薬 Download PDFInfo
- Publication number
- JP2008529537A JP2008529537A JP2007555399A JP2007555399A JP2008529537A JP 2008529537 A JP2008529537 A JP 2008529537A JP 2007555399 A JP2007555399 A JP 2007555399A JP 2007555399 A JP2007555399 A JP 2007555399A JP 2008529537 A JP2008529537 A JP 2008529537A
- Authority
- JP
- Japan
- Prior art keywords
- pathogenic
- prion
- sample
- peptide
- peptide reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 650
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 552
- 102000029797 Prion Human genes 0.000 title claims abstract description 527
- 108091000054 Prion Proteins 0.000 title claims abstract description 527
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 443
- 238000000034 method Methods 0.000 claims abstract description 197
- 239000000203 mixture Substances 0.000 claims abstract description 87
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 37
- 210000000056 organ Anatomy 0.000 claims abstract description 15
- 238000012216 screening Methods 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 207
- 230000027455 binding Effects 0.000 claims description 136
- 239000007787 solid Substances 0.000 claims description 114
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 107
- 229920001184 polypeptide Polymers 0.000 claims description 50
- 102000040430 polynucleotide Human genes 0.000 claims description 49
- 108091033319 polynucleotide Proteins 0.000 claims description 49
- 239000002157 polynucleotide Substances 0.000 claims description 49
- 241001465754 Metazoa Species 0.000 claims description 39
- 239000011324 bead Substances 0.000 claims description 34
- 235000013305 food Nutrition 0.000 claims description 33
- 239000012472 biological sample Substances 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 241000282414 Homo sapiens Species 0.000 claims description 25
- 210000001519 tissue Anatomy 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 20
- 108010049175 N-substituted Glycines Proteins 0.000 claims description 17
- 208000024777 Prion disease Diseases 0.000 claims description 17
- 230000036770 blood supply Effects 0.000 claims description 15
- 210000002381 plasma Anatomy 0.000 claims description 14
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 13
- 210000001772 blood platelet Anatomy 0.000 claims description 10
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 9
- 238000001574 biopsy Methods 0.000 claims description 8
- 239000004793 Polystyrene Substances 0.000 claims description 7
- 230000000389 anti-prion effect Effects 0.000 claims description 7
- 229920002223 polystyrene Polymers 0.000 claims description 7
- 102000013566 Plasminogen Human genes 0.000 claims description 6
- 108010051456 Plasminogen Proteins 0.000 claims description 6
- 239000004816 latex Substances 0.000 claims description 6
- 229920000126 latex Polymers 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000012503 blood component Substances 0.000 claims description 5
- 210000005013 brain tissue Anatomy 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 210000000653 nervous system Anatomy 0.000 claims description 5
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 4
- 229920006318 anionic polymer Polymers 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 229920006317 cationic polymer Polymers 0.000 claims description 4
- 239000013642 negative control Substances 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 239000013641 positive control Substances 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 238000011887 Necropsy Methods 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 229920002620 polyvinyl fluoride Polymers 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 2
- 230000037452 priming Effects 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 73
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 73
- 238000001514 detection method Methods 0.000 abstract description 53
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 238000000746 purification Methods 0.000 abstract description 10
- 238000003745 diagnosis Methods 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000000069 prophylactic effect Effects 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 107
- 102000004169 proteins and genes Human genes 0.000 description 92
- 235000018102 proteins Nutrition 0.000 description 87
- 101710138751 Major prion protein Proteins 0.000 description 63
- 102100025818 Major prion protein Human genes 0.000 description 59
- 235000001014 amino acid Nutrition 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 53
- 229940024606 amino acid Drugs 0.000 description 51
- 150000001413 amino acids Chemical class 0.000 description 46
- 239000000427 antigen Substances 0.000 description 39
- 102000036639 antigens Human genes 0.000 description 39
- 108091007433 antigens Proteins 0.000 description 39
- 238000003556 assay Methods 0.000 description 37
- -1 polypropylene Polymers 0.000 description 33
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 30
- 108010043958 Peptoids Proteins 0.000 description 26
- 102000001708 Protein Isoforms Human genes 0.000 description 26
- 108010029485 Protein Isoforms Proteins 0.000 description 26
- 239000012634 fragment Substances 0.000 description 26
- 239000002671 adjuvant Substances 0.000 description 22
- 239000000306 component Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 18
- 125000005647 linker group Chemical group 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 239000013598 vector Substances 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 15
- 229960002685 biotin Drugs 0.000 description 15
- 235000020958 biotin Nutrition 0.000 description 15
- 239000011616 biotin Substances 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 241000894007 species Species 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- 108010090804 Streptavidin Proteins 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 239000004365 Protease Substances 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 108091005804 Peptidases Proteins 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 229920001577 copolymer Polymers 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 239000011859 microparticle Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 9
- 108010067770 Endopeptidase K Proteins 0.000 description 9
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 9
- 125000003630 glycyl group Chemical class [H]N([H])C([H])([H])C(*)=O 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 8
- 241001494479 Pecora Species 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 235000013930 proline Nutrition 0.000 description 8
- 235000019419 proteases Nutrition 0.000 description 8
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 101100298534 Mus musculus Prnp gene Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 208000008864 scrapie Diseases 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000271566 Aves Species 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 5
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 241000282943 Odocoileus Species 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000001476 gene delivery Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 208000010544 human prion disease Diseases 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 4
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- 101710186708 Agglutinin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102100038124 Plasminogen Human genes 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229940066429 octoxynol Drugs 0.000 description 4
- 229920002113 octoxynol Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000010188 recombinant method Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 229920000037 Polyproline Polymers 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 230000003302 anti-idiotype Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 210000004520 cell wall skeleton Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 108010026466 polyproline Proteins 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 150000003148 prolines Chemical class 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000011895 specific detection Methods 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 2
- JOWMUWBEMDOCKB-UHFFFAOYSA-N 2-(cyclopropylmethylazaniumyl)acetate Chemical compound OC(=O)CNCC1CC1 JOWMUWBEMDOCKB-UHFFFAOYSA-N 0.000 description 2
- KJVDDBLOGFNRTJ-UHFFFAOYSA-N 2-[amino(butyl)amino]acetic acid Chemical compound CCCCN(N)CC(O)=O KJVDDBLOGFNRTJ-UHFFFAOYSA-N 0.000 description 2
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 2
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 2
- 241000282979 Alces alces Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 241000283014 Dama Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 102000002297 Laminin Receptors Human genes 0.000 description 2
- 108010000851 Laminin Receptors Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000920340 Pion Species 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 230000003588 decontaminative effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010023497 kuru Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 108010034897 lentil lectin Proteins 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000008262 pumice Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- OAWXYINGQXLWOE-UHFFFAOYSA-N (2-acetyloxybenzoyl) 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC(=O)C1=CC=CC=C1OC(C)=O OAWXYINGQXLWOE-UHFFFAOYSA-N 0.000 description 1
- ZENNTZUZBRESKJ-ZETCQYMHSA-N (2s)-2-(1-benzothiophen-2-ylamino)propanoic acid Chemical compound C1=CC=C2SC(N[C@@H](C)C(O)=O)=CC2=C1 ZENNTZUZBRESKJ-ZETCQYMHSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 244000003363 Allium ursinum Species 0.000 description 1
- 235000005336 Allium ursinum Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical group C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000350052 Daniellia ogea Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- SGCGMORCWLEJNZ-UWVGGRQHSA-N His-His Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1NC=NC=1)C([O-])=O)C1=CN=CN1 SGCGMORCWLEJNZ-UWVGGRQHSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 description 1
- 101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 description 1
- 101000648491 Homo sapiens Transportin-1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- WRUZLCLJULHLEY-UHFFFAOYSA-N N-(p-hydroxyphenyl)glycine Chemical compound OC(=O)CNC1=CC=C(O)C=C1 WRUZLCLJULHLEY-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102100028748 Transportin-1 Human genes 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004295 calcium sulphite Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006658 host protein synthesis Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical group NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108091000699 pea lectin Proteins 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920000553 poly(phenylenevinylene) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000015 polydiacetylene Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 229920000123 polythiophene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004054 semiconductor nanocrystal Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Abstract
Description
本発明は、プリオンタンパク質と相互作用するペプチド試薬、これらのペプチド試薬をコードするポリヌクレオチド、このようなペプチド試薬およびポリヌクレオチドを使用して抗体を作製する方法ならびにこれらの方法を使用して作製された抗体に関する。本発明は、さらに、サンプル中の病原性プリオンの存在を検出するためにこれらのペプチド試薬を使用する方法および治療的組成物または予防的組成物中の成分としてこれらのペプチド試薬を使用する方法に関する。
タンパク質コンホメーション病は、伝達性海綿状脳症を含む種々の無関係な疾患を含み、それらの疾患は、後に異常タンパク質型の自己会合をもたらすタンパク質(コンホメーション病タンパク質)の異常なコンホメーション遷移に起因し、結果的に組織沈着および損傷が起きる。これらの疾患はまた、臨床像において顕著な類似点、代表的には、診断から種々の長さの潜伏期を経て死を迎えるという進行の速さを共有する。
Harrison’s Principles of Internal Medicine,Isselbacherら、編、McGraw−Hill,Inc.New York(1994) Medoriら、N.Engl.J.Med.(1992)326:444−9 Bolton,McKinleyら、Science(1982)218:1309−1311 Prusiner,Boltonら、Biochemistry(1982)21:6942−6950 McKinley,Boltonら、Cell(1983)35:57−62 Basler,Oeschら、Cell(1986)46:417−428 Zhangら、Biochem.(1997)36(12):3543−3553 Cohen & Prusiner、Ann Rev.Biochem.(1998)67:793−819 Panら、Proc Natl Acad Sci USA(1993)90:10962−10966 Safarら、J Biol Chem(1993)268:20276−20284 Willeら、Proc.Nat’l Acad.Sci.USA(2001)99:3563−3568 Peretzら、J.Mol Biol.(1997)273:614−622 Cohen & Prusiner,Chapter5:Structural Studies of Prion Proteins in PRION BIOLOGY AND DISEASES,ed.S.Prusiner,Cold Spring Harbor Laboratory Press,1999,pp:191−228 Kanekoら、Proc.Nat’l Acad.Sci.USA(1995)92:11160−11164 Caughey、Br Med Bull.(2003)66:109−20 Matsunagaら、PROTEINS:Structure,Function and Genetics(2001)44:110−118
本発明は、プリオンタンパク質と相互作用するペプチド試薬に部分的に関する。より具体的には、本明細書中において記載されるペプチド試薬は、プリオンタンパク質の病原性アイソフォームと優先的に相互作用する。これらのペプチド試薬は、病原性プリオンを単離するためか、またはサンプル中の病原性プリオンの存在を検出するためのツールとして、治療的組成物または予防的組成物の成分として、および/またはプリオン特異的抗体を作製するためなどの幅広い用途において使用することができる。例えば、PrPCと比較して、PrPScと優先的に相互作用するペプチド試薬は、生存被験体から得られたサンプル中の病原型の直接的な検出、例えば、疾患の診断または献血サンプルのスクリーニングまたは臓器提供用の臓器のスクリーニングに有用である。
本発明は、比較的小さいペプチド(50〜100アミノ酸長未満、好ましくは、50アミノ酸長未満およびなおもさらに好ましくは、約30アミノ酸長未満)が、非病原性プリオンタンパク質と病原性プリオンタンパク質とを識別するために使用され得るという驚くべき、予想外の発見に関する。すなわち、本開示は、これらのペプチドおよびそれらの誘導体(ひとまとめにして「ペプチド試薬」)が、異なる特異性および/または親和性で、病原性タンパク質および非病原性タンパク質の形態と結合し得るので、診断試薬/検出試薬として、または治療的組成物の成分としてそれ自体で使用され得るという驚くべき知見に関する。本開示より以前は、大型分子(例えば、抗体、PrPC、α型rPrPおよびプラスミノゲン)だけが、病原型および非病原型を区別するために使用することができると考えられていた。同様に、以前に報告されていた抗原性ペプチドは、病原型と非病原型とを識別する能力について評価された抗体を作製するために使用されていた。しかしながら、プリオンタンパク質が比較的非免疫原性であるという性質に起因して、病原型に特異的な抗体を作製することが困難であると証明されていた。例えば、R.A.Williamsonら、“Antibodies as Tools to Probe Prion Protein Biology” in PRION BIOLOGY AND DISEASES,ed.S.Prusiner,Cold Spring Harbor Laboratory Press,1999,pp:717−741を参照のこと。
本発明の理解を促すために、本出願において使用される、選ばれた用語について、以下に記述する。
「遺伝子導入」または「遺伝子送達」とは、宿主細胞に目的のDNAを確かに挿入するための方法またはシステムのことをいう。このような方法は、組み込まれていない導入されたDNAの一過性の発現、染色体外の複製および導入されたレプリコン(例えば、エピソーム)の発現または導入された遺伝物質の宿主細胞のゲノムDNAへの組み込みをもたらし得る。遺伝子送達発現ベクターとしては、アルファウイルス、ポックスウイルスおよびワクシニアウイルス由来のベクターが挙げられるが、これらに限定されない。免疫するために使用されるとき、このような遺伝子送達発現ベクターは、ワクチンまたはワクチンベクターと呼ばれることがある。
ペプチド試薬(および/またはこれらのペプチド試薬をコードするポリヌクレオチド)を含む組成物が本明細書中に記載され、そのペプチド試薬は、例えば、一方の型と優先的に相互作用するが、他方とは相互作用しないことによって、プリオンタンパク質の病原性アイソフォームと非病原性アイソフォームとを識別することができる。これらのペプチド試薬を使用して作製される抗体だけでなくこれらのペプチド試薬および/または抗体を含む組成物ならびに(例えば、病原性プリオンタンパク質の単離および/または検出のために)これらのペプチド試薬および/または抗体を作製する方法および使用する方法がまた提供される。
コンホメーション病タンパク質の病原型と相互作用するペプチド試薬が本明細書中に記載される。コンホメーション病タンパク質は、本明細書中においてプリオンタンパク質によって代表される。
本発明のペプチド試薬は、すべてが当該分野で周知であるいかなる方法においても作製することができる。このような方法は、米国特許出願番号10/917,646(開示の全体が、本明細書中で参考により援用される)に記載されている。
さらに、本発明において使用される、本明細書中において記載されるペプチド試薬は、米国特許出願公開第10/917,646号に記載されているような抗体を作製するために使用され得る。この開示は、その全体が本明細書中に参考として援用される。
本発明のペプチド試薬は、サンプル(例えば、生物学的サンプル(例えば、血液、脳、脊髄、CSFまたは器官サンプル)をスクリーニングするため、例えば、これらのサンプル中のコンホメーション病タンパク質の病原型の存在の有無を検出するための種々のアッセイにおいて使用され得る。多くの現在のプリオン診断試薬とは異なり、本明細書中において記載されるペプチド試薬は、血液サンプル、血液供給物またはバイオプシーサンプルを含む、実質的にどんなタイプの生物学的サンプルまたは非生物学的サンプルにおいても検出が可能である。
(A.検出)
上で記載したように、本明細書中において記載されるペプチド試薬は、被験体のプリオン病を診断するために使用され得る。さらに、上記のペプチド試薬はまた、任意のサンプル、例えば、血液および/または食品供給物中の病原性プリオンの汚染を検出するために使用され得る。本発明は、サンプルの供給物、例えば、血液供給物または食品供給物からサンプルを選択する方法を提供し、この方法は、病原性プリオンタンパク質を含まないサンプルを選択する工程を含む。すなわち、実質的に病原性プリオンを含まない血液供給物を、本明細書中において記載される検出アッセイのいずれかを使用して、個々の回収されたサンプルまたは貯蔵されたサンプル由来のアリコートをスクリーニングすることにより調製し得る。病原性プリオンで汚染されたサンプルまたは貯蔵されたサンプルは、それらが混合される前に排除され得る。このようにして、実質的に病原性プリオン汚染がない血液供給物が提供され得る。「実質的に病原性プリオンを含まない」とは、本明細書中において記載されるアッセイのいずれを使用しても、病原性プリオンの存在が検出されないことを意味する。重要なことには、本明細書中において記載されるペプチド試薬は、希釈した脳組織中の病原性タンパク質型を、正常組織と比較して106倍検出することがすでに示されており、本明細書中において記載されるペプチド試薬は、血液中の病原性プリオンを検出することが可能であり得る唯一の証明された試薬である。
本発明のペプチドはまた、病原性プリオンを単離する目的(例えば、検出前にプリオンタンパク質を濃縮するため)およびサンプルから病原性プリオンを排除する目的(例えば、実質的に病原性プリオンを含まないサンプルを提供する手段として)の両方のために、サンプルから病原性プリオンを除去するために使用され得る。これらの方法において、ペプチド試薬は、代表的には、固体支持体上に提供される。ペプチド試薬を含む固体支持体を、プリオンがペプチド試薬と結合する条件下で、病原性プリオンを含むサンプルと接触させる。目的が、病原性プリオンを単離することである場合、未結合サンプルは、除去され、そしてプリオンを含む固体支持体が回収される;目的が、サンプルからプリオンを排除することである場合、未結合サンプルが回収される。
本発明は、さらに、本明細書中において記載されるペプチド試薬および/または抗体(ならびにこれらのペプチド試薬および/または抗体をコードするポリヌクレオチド)を含む組成物ならびにプリオン関連疾患の処置または予防のために治療的組成物および予防的組成物においてこれらの組成物を使用する方法に関する。さらに、抗体、ペプチド試薬(ならびにこれらの抗体および/またはペプチド試薬をコードするポリヌクレオチド)はまた、予防的な目的(すなわち、発病を予防するため)または治療的な目的(感染後の疾患を処置するため)のために個別に、または組み合わせて組成物中で使用され得る。
本発明の組成物は、単回用量または投与レジメンの一部として投与され得る。核酸および/またはペプチドが、任意の適当な様式によって投与され得る。その様式としては、筋肉内、粘膜内、皮下、皮内、経皮的、膣内、直腸内、経口的および/または静脈内が挙げられるがこれらに限定されない。投与レジメンは、初回投薬および追加免疫投薬を含み得、経粘膜的、非経口的またはそれらの様々な組み合わせで投与され得る。
プリオンタンパク質のペプチドフラグメントを、本質的に、Merrifield(1969)Advan.Enzymol.32:221およびHolm and Medal(1989),Multiple column peptide synthesis,p.208E,Bayer and G.Jung(ed.),Peptides 1988,Walter de Gruyter & Co.Berlin−N.Y.に記載されているような標準的なペプチド合成技術を使用して化学的に合成した。ペプチドをHPLCで精製し、配列を質量分析によって確認した。
配列番号14(QWNKPSKPKTN、配列番号2の残基97〜107に対応)、配列番号67(KKRPKPGGWNTGG、配列番号2の残基23〜36に対応)および配列番号68(KKRPKPGG、配列番号2の残基23〜30に対応)に示されるペプチドにおいて、ペプトイド置換を行った。特に、これらのペプチドの1個以上のプロリン残基を様々なN置換ペプトイドで置換した。任意のプロリンの代わりに使用され得るペプトイドについては、図3を参照のこと。ペプトイドを、米国特許第5,877,278号および同第6,033,631号(これら両方の全体が、本明細書中において参考として援用される);Simonら、(1992)Proc.Natl.Acad.Sci. USA 89:9367に記載されているように調製および合成した。
特定のペプチド試薬を、例えば、タンデム反復(多コピーのペプチドをGGGなどのリンカーを介して連結する)、複数の抗原性ペプチド(MAPS)および/または直鎖的に連結されたペプチドを調製することによって多量体として調製した。
ペプチドを、合成および精製の後に標準的な技術を使用してビオチン化した。ビオチンを、ペプチドのN末端またはC末端に付加した。
(A.プルダウン)
本明細書中で記載されるようなペプチド試薬を、磁気ビーズプルダウンアッセイを使用して、プリオンタンパク質に特異的に結合する能力について試験した。このアッセイに向けて、ペプチド試薬をビオチンで標識し、これにより、ストレプトアビジンコートされた磁気ビーズへの結合が可能となった。
ウエスタンブロッティング解析を以下のとおり実施した。上記のように沈降したビーズ−ペプチド−プリオン複合体を、各チューブに加えられる25〜30μlのSDS緩衝液(Novex Tris−グリシンSDS−サンプル緩衝液2×)を加えることによる最終的な洗浄のあと、変性した。そのチューブを、すべてのビーズが懸濁するまでボルテックスにより混合した。そのチューブを、その蓋が開くまで煮沸し、標準的なSDS−PAGEゲルで泳動し、そしてWB解析に向けて固体メンブレンに転写した。
最後の洗浄後、上記のビーズ−ペプチド複合体をチオシアン酸グアニジンで変性し、以前にRyouら、(2003)Lab Invest.83(6):837−43に記載されたような変性タンパク質を用いてELISAを実施した。ブランクコントロール(.172〜.259の範囲)よりも高いO.D.値を陽性とみなした。
ウエスタンブロッティングおよびELISA結合アッセイの結果を表2にまとめた。簡潔には、PrPScに結合する、本明細書中で記載されるようなペプチド試薬の特異的な結合を検出するために、脳ホモジネートのプロテイナーゼK消化は、必要ではなかった。図4に示すように、野生型脳ホモジネートへの結合は観察されなかったことから、ペプチド試薬がPrPScに特異的に結合したことが示唆される。さらに、上記のウエスタンブロッティング解析では、4対数希釈以上でPrPScが検出されたが、ELISAはウエスタンブロッティングよりも少なくとも10倍以上感度が高かった。
2:環化
3:示された位置でGGGG残基を付加/挿入した
4:示された位置でGGG残基を付加/挿入した
5:示された位置でGG残基を付加/挿入した
6:示された位置でKKK残基を付加/挿入した
ND=試験せず
結合に関連する残基を同定するために、アラニンスキャニングも実施した。結果を表3に示す。
以下において、本発明のペプチド試薬に対する抗体を作製するために使用され得るプロトコールの実施例を提供する。
Claims (49)
- 請求項3に記載のペプチド試薬であって、該ペプチド試薬は、N末端および/またはC末端に、n=1、2、3または4であるアミノ酸配列(G)nを含む、ペプチド試薬。
- ビオチン化されている、請求項3または4に記載のペプチド試薬。
- N末端および/またはC末端に、n=1、2、3または4であるアミノ酸配列(G)nを含む、請求項6に記載のペプチド試薬。
- ビオチン化された、請求項6または7に記載のペプチド試薬。
- 配列番号136を有するペプチドから誘導される、請求項2に記載のペプチド試薬。
- ビオチン化されている、請求項9に記載のペプチド試薬。
- 1個以上のプロリン残基が存在する場合、該1個以上のプロリン残基は、N置換グリシンで置換されている、請求項1に記載のペプチド試薬。
- 請求項1に記載のペプチド試薬をコードするポリヌクレオチド。
- 請求項1に記載のペプチド試薬および病原性プリオンタンパク質を含む複合体。
- サンプル中の病原性プリオンの存在を検出するための方法であって、該方法は以下の工程:
(a)病原性プリオンが存在する場合に、病原性プリオンを含むと疑われるサンプルと、請求項1に記載の第1のペプチド試薬とを、該第1のペプチド試薬が該病原性プリオンタンパク質に結合し得る条件下で接触させ、第1の複合体を形成する工程;および
(b)該病原性プリオンが存在する場合に、該第1のペプチド試薬への該病原性プリオンの結合によってサンプル中の該病原性プリオンの存在を検出する工程
を含む、方法。 - 前記第1のペプチド試薬が、検出可能に標識されている、請求項14に記載の方法。
- 前記第1のペプチド試薬が、ビオチン化されている、請求項15に記載の方法。
- 前記第1のペプチド試薬が、固体支持体に結合している、請求項14に記載の方法。
- サンプル中の病原性プリオンの存在を検出するための方法であって、該方法は、以下の工程:
(a)病原性プリオンが存在する場合、病原性プリオンを含むと疑われるサンプルと、請求項1に記載の第1のペプチド試薬とを、該第1のペプチド試薬が該病原性プリオンに結合し得る条件下で接触させ、第1の複合体を形成する工程;
(b)該第1の複合体と、請求項1に記載の第2のペプチド試薬とを、該第2のペプチド試薬が該第1の複合体中の該病原性プリオンに結合し得る条件下で接触させる工程であって、ここで、該第2のペプチド試薬は、検出可能な標識を含む、工程;および
(c)病原性プリオンが存在する場合、該第2のペプチド試薬への該病原性プリオンの結合によって該サンプル中の該病原性プリオンの存在を検出する工程
を含む、方法。 - 前記第1のペプチド試薬と前記第2のペプチド試薬とが、異なっている、請求項18に記載の方法。
- 前記第1のペプチド試薬と前記第2のペプチド試薬とが、同じである、請求項18に記載の方法。
- 前記第1のペプチド試薬が、固体支持体に結合している、請求項18に記載の方法。
- 前記第1のペプチド試薬が、ビオチン化されている、請求項18に記載の方法。
- サンプル中の病原性プリオンの存在を検出するための方法であって、該方法は、以下の工程:
(a)病原性プリオンが存在する場合、病原性プリオンを含むと疑われるサンプルと、請求項1に記載の第1のペプチド試薬とを、該第1のペプチド試薬が該病原性プリオンに結合し得る条件下で接触させ、第1の複合体を形成する工程;
(b)未結合サンプル物質を除去する工程;
(c)該第1の複合体から該病原性プリオンを解離する工程;
(d)該解離された病原性プリオンと、請求項1に記載の第2のペプチド試薬とを、該第2のペプチド試薬が該病原性プリオンに結合し得る条件下で接触させる工程であって、ここで、該第2のペプチド試薬は、検出可能な標識を含む、工程;および
(e)該病原性プリオンが存在する場合、該第2のペプチド試薬への該病原性プリオンの結合によって該サンプル中の該病原性プリオンの存在を検出する工程
を含む、方法。 - サンプル中の病原性プリオンの存在を検出するための方法であって、該方法は、以下の工程:
(a)病原性プリオンが存在する場合、病原性プリオンを含むと疑われるサンプルと、請求項1に記載の第1のペプチド試薬とを、該第1のペプチド試薬が該病原性プリオンに結合し得る条件下で接触させ、第1の複合体を形成する工程;
(b)未結合サンプル物質を除去する工程;
(c)該第1の複合体から該病原性プリオンを解離する工程;
(d)該解離された病原性プリオンと、プリオン結合試薬とを、該プリオン結合試薬が該病原性プリオンに結合し得る条件下で接触させる工程であって、ここで、該プリオン結合試薬は、検出可能な標識を含む、工程;および
(e)該病原性プリオンが存在する場合、該プリオン結合試薬への該病原性プリオンの結合によって該サンプル中の該病原性プリオンの存在を検出する工程
を含む、方法。 - 前記プリオン結合試薬が、抗プリオン抗体、モチーフグラフト化ハイブリッドポリペプチド、陽イオン性または陰イオン性のポリマー、増殖触媒およびプラスミノゲンからなる群から選択される、請求項24に記載の方法。
- サンプル中の病原性プリオンの存在を検出するための方法であって、該方法は、以下の工程:
(a)病原性プリオンが存在する場合、病原性プリオンを含むと疑われるサンプルと、プリオン結合試薬とを、該プリオン結合試薬が該病原性プリオンを結合し得る条件下で接触させ、第1の複合体を形成する工程;
(b)未結合サンプル物質を除去する工程;
(c)該第1の複合体と、請求項1に記載のペプチド試薬とを、該ペプチド試薬が該病原性プリオンに結合し得る条件下で接触させる工程であって、ここで、該ペプチド試薬は、検出可能な標識を含む、工程;および
(d)該病原性プリオンが存在する場合、該ペプチド試薬への該病原性プリオンの結合によって、該サンプル中の該病原性プリオンの存在を検出する工程
を含む、方法。 - サンプル中の病原性プリオンを検出するための方法であって、該方法は、以下の工程:
(a)請求項1に記載の第1のペプチド試薬を含む固体支持体を提供する工程;
(b)サンプル中に病原性プリオンが存在するとき、該固体支持体と該サンプルとを、該病原性プリオンが該第1のペプチド試薬に結合し得る条件下で接触させる工程であって;
該固体支持体と、請求項1に記載の検出可能に標識された第2のペプチド試薬とを、該第2のペプチド試薬が該第1のペプチド試薬によって結合された病原性プリオンに結合し得る条件下で接触させる工程;および
(c)該第1のペプチド試薬と、該サンプルに由来する病原性プリオンと、該第2のペプチド試薬との間に形成された複合体を検出することによって、該サンプル中の該病原性プリオンの存在を検出する工程
を含む、方法。 - サンプル中の病原性プリオンの存在を検出するための方法であって、該方法は、以下の工程:
(a)プリオン結合試薬を含む固体支持体を提供する工程;
(b)プリオンタンパク質がサンプル中に存在するとき、該固体支持体と該サンプルとを、該プリオンタンパク質が該プリオン結合試薬に結合し得る条件下で接触させる工程;
(c)該固体支持体と請求項1に記載の検出可能に標識された第2のペプチド試薬とを接触させる工程;および
(d)該プリオン結合試薬と、該生物学的サンプル由来の病原性プリオンと、該第2のペプチド試薬との間に形成された複合体を検出する工程
を含む、方法。 - サンプル中の病原性プリオンの存在を検出するための方法であって、該方法は、以下の工程:
(a)請求項1に記載の第1のペプチド試薬を含む固体支持体を提供する工程;
(b)該固体支持体と、検出可能に標識された第1のリガンドとを混合する工程であって、ここで、該検出可能に標識された第1のリガンドに対する該第1のペプチド試薬の結合親和性は、病原性プリオンに対する該第1のペプチド試薬の結合親和性よりも弱い、工程;
(c)病原性プリオンがサンプル中に存在するとき、該病原性プリオンが該第1のペプチド試薬に結合し、そして該第1のリガンドを置換し得る条件下で該サンプルと該固体支持体とを混合する工程;
(d)該第1のペプチド試薬と該サンプル由来の該病原性プリオンとの間に形成された複合体を検出する工程
を含む、方法。 - 前記固体支持体が、ニトロセルロース、ポリスチレンラテックス、ポリビニルフルオライド、ジアゾ化ペーパー、ナイロン膜、活性化ビーズおよび磁気的反応性ビーズからなる群から選択される、請求項17に記載の方法。
- 前記サンプルが、生物学的サンプルである、請求項14に記載の方法。
- 前記生物学的サンプルが、器官、全血、血液画分、血液成分、血漿、血小板、血清、脳脊髄液(CSF)、脳組織、神経系組織、筋組織、骨髄、尿、涙、非神経系組織、器官および/またはバイオプシーもしくはネクロプシーからなる群から選択される、請求項31に記載の方法。
- 前記生物学的サンプルが、全血、血漿、血小板、血液画分または血清である、請求項32に記載の方法。
- 請求項1に記載の少なくとも1つのペプチド試薬を含む、固体支持体。
- サンプル中の病原性プリオンの存在を検出するためのキットであって:
(a)請求項34に記載の固体支持体;および
他に必要な試薬ならびに必要であれば、ポジティブコントロールおよびネガティブコントロールを備える、キット。 - 請求項1に記載のペプチド試薬を含む組成物。
- 請求項12に記載のポリヌクレオチドを含む組成物。
- 請求項36に記載の1個以上の組成物を動物に投与する工程を含む、プリオン病を処置または予防する方法。
- 前記被験体が、哺乳動物である、請求項38に記載の方法。
- 前記哺乳動物が、ヒトである、請求項39に記載の方法。
- 前記組成物が、筋肉内、粘膜内、鼻腔内、皮下、皮内、経皮的、膣内、直腸内、経口的または静脈内に投与される、請求項38に記載の方法。
- プリオン病を処置または予防する方法であって、該方法は、以下の工程
(a)初回刺激工程において請求項36に記載の組成物を含む第1の組成物を投与する工程および
(b)追加免疫として、被験体において免疫応答を誘発するのに十分な量の請求項36に記載の組成物を含む第2の組成物を投与する工程
を含む、方法。 - サンプルから病原性プリオンタンパク質を単離するための方法であって、該方法は、以下の工程:
(a)請求項34に記載のペプチド試薬を含む固体支持体を提供する工程;
(b)該サンプルと該固体支持体とを、該サンプル中に病原性プリオンタンパク質が存在する場合、該病原性プリオンタンパク質が前記第1のペプチド試薬に結合し得る条件下で接触させ、第1の複合体を形成する工程および
(c)未結合サンプル物質を除去する工程
を含む、方法。 - 前記第1の複合体から前記病原性プリオンタンパク質を解離する工程をさらに含む、請求項43に記載の方法。
- サンプルから病原性プリオンタンパク質を排除するための方法であって、該方法は、以下の工程;
(a)請求項34に記載のペプチド試薬を含む固体支持体を提供する工程;
(b)該固体支持体と、病原性プリオンタンパク質を含むと疑われるサンプルとを、病原性プリオンタンパク質が存在する場合、該病原性プリオンタンパク質が該ペプチド試薬に結合し得る条件下で、接触させる工程;および
(c)未結合サンプル物質を回収する工程
を含む、方法。 - サンプルの供給物からサンプルを選択するための方法であって、請求項1に記載のペプチド試薬と優先的に相互作用する病原性プリオンタンパク質を含まないサンプルを選択する工程を含む、方法。
- サンプルの供給物からサンプルを選択するための方法であって、請求項1に記載のペプチド試薬と優先的に相互作用する病原性プリオンタンパク質を含むサンプルを選択する工程を含む、方法。
- 実質的に病原性プリオンを含まない血液供給物を調製する方法であって、該血液供給物は、全血、血漿、血小板または血清を含み、該方法は、以下の工程:
(a)回収された血液サンプルから、全血、血漿、血小板または血清のアリコートを、請求項14に記載の方法によってスクリーニングする工程;
(b)病原性プリオンが検出されたサンプルを排除する工程;および
(c)病原性プリオンが検出されなかったサンプルを混合し、実質的に病原性プリオンを含まない血液供給物を提供する工程
を含む、方法。 - 実質的に病原性プリオンを含まない食品供給物を調製する方法であって、該方法は、以下の工程:
(a)該食品供給物に入る生存生物体から回収されたサンプルまたは該食品供給物に入ることが意図された食物から回収されたサンプルを、請求項14に記載の方法によってスクリーニングする工程;
(b)病原性プリオンが検出されたサンプルを排除する工程;および
(c)病原性プリオンが検出されなかったサンプルを混合し、実質的に病原性プリオンを含まない食品供給物を提供する工程
を含む、方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/056,950 US20060035242A1 (en) | 2004-08-13 | 2005-02-11 | Prion-specific peptide reagents |
PCT/US2006/007001 WO2006086799A2 (en) | 2005-02-11 | 2006-02-07 | Prion-specific peptide reagents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011289829A Division JP2012080899A (ja) | 2005-02-11 | 2011-12-28 | プリオン特異的なペプチド試薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008529537A true JP2008529537A (ja) | 2008-08-07 |
JP2008529537A5 JP2008529537A5 (ja) | 2009-04-02 |
Family
ID=36793844
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007555399A Pending JP2008529537A (ja) | 2005-02-11 | 2006-02-07 | プリオン特異的なペプチド試薬 |
JP2011289829A Pending JP2012080899A (ja) | 2005-02-11 | 2011-12-28 | プリオン特異的なペプチド試薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011289829A Pending JP2012080899A (ja) | 2005-02-11 | 2011-12-28 | プリオン特異的なペプチド試薬 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20060035242A1 (ja) |
EP (1) | EP1858537A4 (ja) |
JP (2) | JP2008529537A (ja) |
WO (1) | WO2006086799A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012108035A (ja) * | 2010-11-18 | 2012-06-07 | Sumika Chemical Analysis Service Ltd | 免疫反応測定用担体及びその製造方法ならびにこれを用いた免疫反応測定用装置、免疫反応測定用キット及び免疫反応測定方法 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050026165A1 (en) * | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
MXPA03011000A (es) * | 2001-05-31 | 2004-02-27 | Arete Associates | Metodo de sensor de proteinas deformadas. |
US20060035242A1 (en) * | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
US20060057671A1 (en) * | 2004-09-10 | 2006-03-16 | Orser Cindy S | Immobilized probes and methods of detecting conformationally altered prion proteins |
US20090130774A1 (en) * | 2005-01-13 | 2009-05-21 | David Peretz | Elisa assays using prion-specific peptide reagents |
US20090099343A1 (en) * | 2005-01-13 | 2009-04-16 | David Peretz | Isolation of pathogenic prions |
WO2006076683A2 (en) * | 2005-01-13 | 2006-07-20 | Novartis Vaccines And Diagnostics Inc. | Isolation and detection of pathogenic prions |
AU2006214463B2 (en) * | 2005-02-15 | 2012-08-30 | Presympto, Inc. | Method for detecting misfolded proteins and prions |
JP5209477B2 (ja) * | 2005-09-09 | 2013-06-12 | ノバルティス アーゲー | プリオンに特異的なペプトイド試薬 |
US8673579B2 (en) * | 2006-07-28 | 2014-03-18 | Adlyfe, Inc. | Peptide probes for diagnostics and therapeutics |
US20100291598A1 (en) * | 2007-04-04 | 2010-11-18 | David Peretz | Prion elisa |
ATE530914T1 (de) * | 2007-04-04 | 2011-11-15 | Novartis Ag | Prionentest |
EP2282753A1 (en) * | 2008-04-30 | 2011-02-16 | Novartis AG | Assay for pathogenic conformers |
AU2010315133B2 (en) * | 2009-11-04 | 2015-09-10 | Novartis Ag | Positively charged species as binding reagents in the separation of protein aggregates from monomers |
JP2013537971A (ja) * | 2010-09-13 | 2013-10-07 | アッヴィ・インコーポレイテッド | 高感度なモノクローナル抗体残留物検出アッセイ |
US8999937B2 (en) | 2011-02-28 | 2015-04-07 | Indiana University Research And Technology Corporation | Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis |
WO2013166183A2 (en) * | 2012-05-02 | 2013-11-07 | Samuel Bogoch | Replikin sequences and their antibodies for diagnostics, therapeutics, and vaccines against prion and neurodegenerative disorders including alzheimer's disease |
EP3370518B1 (en) | 2015-10-14 | 2023-08-23 | X-Therma, Inc. | Compositions and methods for reducing ice crystal formation |
WO2020157381A1 (en) * | 2019-01-29 | 2020-08-06 | Teknologian Tutkimuskeskus Vtt Oy | Methods for screening polypeptides capable of binding specific target molecules and tools related thereto |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004029072A2 (en) * | 2002-09-27 | 2004-04-08 | Caprion Pharmaceuticals Inc. | PrPsc -INTERACTING MOLECULES AND USES THEREOF |
WO2005016127A2 (en) * | 2003-08-13 | 2005-02-24 | Chiron Corporation | Prion-specific peptide reagents |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015903A1 (de) * | 1997-09-19 | 1999-04-01 | Evotec Biosystems Ag | Verfahren zur messung der assoziation von teilstrukturen pathologischer proteinablagerungen |
US3770380A (en) | 1971-04-19 | 1973-11-06 | Us Army | Article and method for multiple immune adherence assay |
US4006117A (en) * | 1973-01-24 | 1977-02-01 | Hooker Chemicals & Plastics Corporation | Amine phosphite antioxidants |
US3843443A (en) * | 1973-03-30 | 1974-10-22 | J Fishman | Polypeptide materials bound to fluorocarbon polymers |
US4011308A (en) | 1974-01-04 | 1977-03-08 | General Electric Company | Method for surface immunological detection of biological particles by the use of tagged antibodies |
US3876504A (en) | 1974-06-10 | 1975-04-08 | Early Warning Co | Procedure for determination of antigens and antibodies and articles for use therewith |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4244721A (en) * | 1979-01-31 | 1981-01-13 | Pedro Buarque De Macedo | Method of making composite borosilicate glass articles |
US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4372745A (en) | 1979-12-19 | 1983-02-08 | Electro-Nucleonics, Inc. | Chemical luminescence amplification substrate system for immunochemistry involving microencapsulated fluorescer |
US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
DE3167442D1 (en) | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
US4341761A (en) | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
US4466917A (en) | 1981-02-12 | 1984-08-21 | New York University | Malaria vaccine |
US4493890A (en) | 1981-03-23 | 1985-01-15 | Miles Laboratories, Inc. | Activated apoglucose oxidase and its use in specific binding assays |
US4399121A (en) | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
US4427783A (en) | 1981-12-14 | 1984-01-24 | Hoffmann-La Roche Inc. | Immunoassay of thymosin α1 |
US4507230A (en) * | 1982-05-12 | 1985-03-26 | Research Corporation | Peptide synthesis reagents and method of use |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4952496A (en) * | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
DE3500180A1 (de) * | 1985-01-04 | 1986-07-10 | Ernst Prof. Dr. 7400 Tübingen Bayer | Pfropfcopolymerisate aus vernetzten polymeren und polyoxyethylen, verfahren zu ihrer herstellung und ihre verwendung |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
US4663161A (en) | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
US4871488A (en) | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
US4722890A (en) | 1985-08-27 | 1988-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Quantitative assay for human terminal complement cascade activation |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4816467A (en) | 1987-01-09 | 1989-03-28 | Farmitalia Carlo Erba S.R.L | Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5292814A (en) * | 1987-04-29 | 1994-03-08 | Ernst Bayer | Process for the preparation of monodispersed polymer beads |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
ES2082850T3 (es) * | 1989-02-24 | 1996-04-01 | Univ California | Inmunoglobulinas preparadas geneticamente. |
CA2049042A1 (en) | 1989-03-10 | 1990-09-11 | Mark L. Collins | Preventing interference with affinity capture schemes |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5306812A (en) * | 1989-09-08 | 1994-04-26 | The Regents Of The University Of California | Immunoglobulin-binding polypeptides |
US5231167A (en) * | 1989-09-08 | 1993-07-27 | The Regents Of The University Of California | Immunoglobulin-binding polypeptides |
US6075121A (en) * | 1990-05-15 | 2000-06-13 | Chiron Corporation | Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such |
GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
WO1992002822A1 (en) * | 1990-08-06 | 1992-02-20 | Cetus Corporation | Methods for the identification of cytokine convertase inhibitors |
US5288707A (en) | 1990-08-13 | 1994-02-22 | Sandoz Ltd. | Borolysine peptidomimetics |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1992011933A1 (en) * | 1991-01-04 | 1992-07-23 | Perseptive Biosystems, Inc. | Sulfonamide bonded hydrophilic coatings |
US5665539A (en) | 1991-07-12 | 1997-09-09 | The Regents Of The University Of California | Immuno-polymerase chain reaction system for antigen detection |
US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
JPH05149949A (ja) | 1991-11-26 | 1993-06-15 | Nisshin Flour Milling Co Ltd | 新規な微量物質測定法 |
JP4233604B2 (ja) * | 1991-12-03 | 2009-03-04 | プロセリックス メディスンズ ディベロップメント リミテッド | プリオンタンパク質のフラグメント |
US5424413A (en) | 1992-01-22 | 1995-06-13 | Gen-Probe Incorporated | Branched nucleic acid probes |
TW327194B (en) * | 1992-05-01 | 1998-02-21 | American Cyanamid Co | Novel amyloid precursor proteins and methods of using same |
DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
US5831005A (en) | 1992-09-24 | 1998-11-03 | Chiron Corporation | Synthesis of N-substituted oligomers |
US5652138A (en) * | 1992-09-30 | 1997-07-29 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
US5591601A (en) | 1993-05-14 | 1997-01-07 | Ohio University Edison Animal Biotechnology Institute | DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5792901A (en) | 1994-05-13 | 1998-08-11 | The Regents Of The University Of California | Detecting prions in a sample and prion preparation and transgenic animal used for same |
US5908969A (en) | 1994-05-13 | 1999-06-01 | The Regents Of The University Of California | Method of detecting prions in a sample and transgenic animal used for same |
US5565186A (en) | 1994-05-13 | 1996-10-15 | The Regents Of The University Of California | Method of detecting prions in a sample and transgenic animal used for same |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6168776B1 (en) * | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
US5639581A (en) * | 1994-10-24 | 1997-06-17 | Fuji Xerox Co., Ltd. | Charge transporting polymer, process for producing the same, and organic electronic device containing the same |
US5854215A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
AU707484B2 (en) * | 1995-09-14 | 1999-07-08 | Regents Of The University Of California, The | Antibodies specific for native PrPsc |
US5750361A (en) * | 1995-11-02 | 1998-05-12 | The Regents Of The University Of California | Formation and use of prion protein (PRP) complexes |
US5985557A (en) | 1996-01-24 | 1999-11-16 | Third Wave Technologies, Inc. | Invasive cleavage of nucleic acids |
US6090606A (en) | 1996-01-24 | 2000-07-18 | Third Wave Technologies, Inc. | Cleavage agents |
US6586193B2 (en) | 1996-04-25 | 2003-07-01 | Genicon Sciences Corporation | Analyte assay using particulate labels |
US6251433B1 (en) * | 1996-08-13 | 2001-06-26 | Chiron Corporation | Polycationic polymers |
ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB2319607A (en) | 1996-11-23 | 1998-05-27 | Electrophoretics International | Detection of prion proteins in mononuclear cells |
US6172043B1 (en) * | 1997-01-10 | 2001-01-09 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides |
EP0861900A1 (en) * | 1997-02-21 | 1998-09-02 | Erziehungsdirektion Of The Canton Zurich | Immunological detection of prions |
US5891641A (en) * | 1997-02-21 | 1999-04-06 | The Regents Of The University Of California | Assay for disease related conformation of a protein |
US20010001061A1 (en) * | 1997-02-21 | 2001-05-10 | Prusiner Stanley B. | Assay for disease related conformation of a protein |
JP2001513776A (ja) | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | LPS関連障害の処置における非メチル化CpGジヌクレオチドを含む核酸の使用 |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
US6787319B2 (en) * | 1997-04-16 | 2004-09-07 | American Home Products Corp. | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
US7005295B1 (en) * | 1997-04-16 | 2006-02-28 | Wyeth | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
JP4727769B2 (ja) | 1997-04-28 | 2011-07-20 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 試薬再循環を用いてオリゴマー、特に、ペプトイドを合成するための装置 |
ATE370740T1 (de) | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
US5962669A (en) * | 1997-06-02 | 1999-10-05 | The Regents Of The University Of California | Nucleic acid encoding prion protein variant |
CA2291483C (en) | 1997-06-06 | 2012-09-18 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
US6214565B1 (en) * | 1998-10-09 | 2001-04-10 | The Regents Of The University Of California | Assay for disease related conformation of a protein and isolating same |
HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
EP1073723B1 (en) * | 1998-04-14 | 2005-08-17 | Sugen, Inc. | Ste20-related protein kinases |
US6211149B1 (en) * | 1998-08-03 | 2001-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors of formation of protease resistant prion protein |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
PT1126876E (pt) | 1998-10-16 | 2007-04-30 | Glaxosmithkline Biolog Sa | Sistemas adjuvantes e vacinas |
GB2348203B (en) * | 1998-11-04 | 2002-06-19 | Imp College Innovations Ltd | Solube beta-forms of prion proteins, methods of preparation and use |
US6329201B1 (en) | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
US6551843B1 (en) | 1999-01-29 | 2003-04-22 | Immunivest Corporation | Methods for enhancing binding interactions between members of specific binding pairs |
AU764969B2 (en) | 1999-04-19 | 2003-09-04 | Smithkline Beecham Biologicals (Sa) | Vaccines |
GB9912743D0 (en) | 1999-06-02 | 1999-08-04 | Proteome Sciences Plc | Method and kit for ligand assay |
IL148672A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
CO5200838A1 (es) | 1999-09-24 | 2002-09-27 | Smithkline Beecham Corp | Vacunas |
EP1216258A1 (en) * | 1999-09-28 | 2002-06-26 | Universität Zürich | Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
WO2001031056A2 (fr) | 1999-10-27 | 2001-05-03 | Universite De Liege | Methode de detection par pcr |
FR2801106B1 (fr) * | 1999-11-12 | 2007-10-05 | Commissariat Energie Atomique | Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc |
US6235483B1 (en) | 2000-01-31 | 2001-05-22 | Agilent Technologies, Inc. | Methods and kits for indirect labeling of nucleic acids |
KR20020081330A (ko) * | 2000-02-16 | 2002-10-26 | 노오쓰웨스턴 유니버시티 | 폴리펩토이드 폐 계면활성제 |
EP1272509A2 (en) * | 2000-04-05 | 2003-01-08 | V.I. Technologies, Inc. | Prion-binding peptidic ligands and methods of using same |
WO2001083107A2 (en) * | 2000-04-28 | 2001-11-08 | Synuthane International, Inc. | Double metal cyanide catalysts containing polyglycol ether complexing agents |
US6511809B2 (en) | 2000-06-13 | 2003-01-28 | E. I. Du Pont De Nemours And Company | Method for the detection of an analyte by means of a nucleic acid reporter |
AU6887101A (en) * | 2000-06-20 | 2002-01-02 | Caprion Pharmaceuticals, Inc. | Copolymers and methods of treating prion-related diseases |
US6505025B2 (en) * | 2000-06-22 | 2003-01-07 | Kyocera Corporation | Color image forming apparatus and process |
US6537548B1 (en) | 2000-07-27 | 2003-03-25 | The Regents Of The University Of California | Antibodies specific for ungulate PrP |
US20030092613A1 (en) * | 2000-08-14 | 2003-05-15 | Lee Daniel H. S. | Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides |
US6721761B2 (en) * | 2000-12-20 | 2004-04-13 | American Management Systems, Inc. | System for assigning digital identifiers to telephone numbers and IP numbers |
US20050026165A1 (en) * | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
MXPA03011000A (es) * | 2001-05-31 | 2004-02-27 | Arete Associates | Metodo de sensor de proteinas deformadas. |
CA2466841A1 (en) * | 2001-11-21 | 2003-06-05 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
EP1478931B2 (en) * | 2002-02-28 | 2018-11-07 | Microsens Biophage Limited | Binding of pathological forms of prion proteins |
US7939641B2 (en) | 2002-04-09 | 2011-05-10 | The Scripps Research Institute | Motif-grafted hybrid polypeptides and uses thereof |
US20040208919A1 (en) * | 2002-06-13 | 2004-10-21 | Nicolau Yves C. | Vaccination against prion diseases |
DE10230141B4 (de) * | 2002-07-04 | 2004-07-15 | Priontype Gmbh | Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc) |
EP1382971A1 (en) * | 2002-07-17 | 2004-01-21 | Pepscan Systems B.V. | Detection of prion disease |
EP2317317B1 (en) * | 2002-12-03 | 2014-11-26 | North Carolina State University | Prion protein ligands and methods of use |
PL1615992T3 (pl) * | 2003-04-04 | 2014-03-31 | Pathogen Removal And Diagnostic Tech Inc | Materiały wiążące białko prionowe i sposoby ich zastosowania |
WO2004092197A2 (en) * | 2003-04-07 | 2004-10-28 | The Regents Of The University Of California | Amyloid-specific peptides and uses thereof |
US20060035242A1 (en) * | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
JP3910569B2 (ja) * | 2003-08-19 | 2007-04-25 | 独立行政法人科学技術振興機構 | アミロイドβ蛋白質のアミロイド線維化を増幅するための試薬 |
US20060057671A1 (en) * | 2004-09-10 | 2006-03-16 | Orser Cindy S | Immobilized probes and methods of detecting conformationally altered prion proteins |
US7482172B2 (en) * | 2005-09-19 | 2009-01-27 | Ortho-Clinical Diagnostics, Inc. | Peptides for discrimination of prions |
US20090099343A1 (en) * | 2005-01-13 | 2009-04-16 | David Peretz | Isolation of pathogenic prions |
US20090130774A1 (en) * | 2005-01-13 | 2009-05-21 | David Peretz | Elisa assays using prion-specific peptide reagents |
JP5209477B2 (ja) * | 2005-09-09 | 2013-06-12 | ノバルティス アーゲー | プリオンに特異的なペプトイド試薬 |
CN102847538B (zh) | 2007-07-06 | 2016-07-06 | M技术株式会社 | 由球碳形成的结晶的制造方法及制造装置 |
-
2005
- 2005-02-11 US US11/056,950 patent/US20060035242A1/en not_active Abandoned
-
2006
- 2006-02-07 EP EP06736343A patent/EP1858537A4/en not_active Withdrawn
- 2006-02-07 JP JP2007555399A patent/JP2008529537A/ja active Pending
- 2006-02-07 WO PCT/US2006/007001 patent/WO2006086799A2/en active Search and Examination
-
2008
- 2008-03-27 US US12/079,573 patent/US20090061462A1/en not_active Abandoned
-
2011
- 2011-12-28 JP JP2011289829A patent/JP2012080899A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004029072A2 (en) * | 2002-09-27 | 2004-04-08 | Caprion Pharmaceuticals Inc. | PrPsc -INTERACTING MOLECULES AND USES THEREOF |
WO2005016127A2 (en) * | 2003-08-13 | 2005-02-24 | Chiron Corporation | Prion-specific peptide reagents |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012108035A (ja) * | 2010-11-18 | 2012-06-07 | Sumika Chemical Analysis Service Ltd | 免疫反応測定用担体及びその製造方法ならびにこれを用いた免疫反応測定用装置、免疫反応測定用キット及び免疫反応測定方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2006086799A3 (en) | 2007-03-01 |
US20060035242A1 (en) | 2006-02-16 |
EP1858537A2 (en) | 2007-11-28 |
US20090061462A1 (en) | 2009-03-05 |
WO2006086799A2 (en) | 2006-08-17 |
JP2012080899A (ja) | 2012-04-26 |
EP1858537A4 (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008529537A (ja) | プリオン特異的なペプチド試薬 | |
JP4709149B2 (ja) | プリオン特異的ペプチド試薬 | |
JP5162250B2 (ja) | プリオン特異的ペプチド試薬を使用するelisaアッセイ | |
JP2008527382A5 (ja) | ||
US20090099343A1 (en) | Isolation of pathogenic prions | |
RU2381033C2 (ru) | Специфичные в отношении прионов пептидные реагенты | |
US20090191571A1 (en) | Isolation and Detection of Pathogenic Prions | |
ZA200601233B (en) | Prion-specific peptide reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090204 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110706 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111005 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111013 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111111 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111205 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111228 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120814 |